FDA Approval for Genotropin in Growth Disorders
Genotropin (somatropin) is approved by the FDA for treating growth failure in children with conditions like growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, or idiopathic short stature (ISS). The label specifies use before epiphyseal closure, typically by age 14-16 in girls and 16-18 in boys, when growth plates fuse and height growth stops.[1]
How Age Limits Are Determined
Treatment effectiveness depends on open growth plates, confirmed via X-ray of the hand/wrist (bone age assessment). Maximum starting age aligns with puberty completion:
- Girls: Often up to 14-15 years if bone age <14 years.
- Boys: Up to 16-17 years if bone age <16 years.
Guidelines from the Pediatric Endocrine Society recommend initiating before closure for at least 6-12 months of potential growth response.[2][3]
What Happens If Started After Puberty?
Post-epiphyseal closure, Genotropin provides no height gain but may be approved for adults with GHD to manage body composition, bone density, and metabolism—not growth.[1] Starting late in eligible kids yields minimal response; studies show <2 cm/year gain if bone age exceeds 14 years.[4]
Off-Label Use and International Guidelines
In Europe (EMA approval), similar limits apply, with maximum start around 14 years for girls and 16 for boys in GHD.[5] Some clinics consider up to age 18 for late maturers with open plates, but evidence is limited and not standard.
Monitoring and When to Stop
Dose starts at 0.16-0.24 mg/kg/week, adjusted by IGF-1 levels and growth velocity. Discontinue if no response after 6 months or at closure. Risks include scoliosis worsening or glucose intolerance in older starts.[1][2]
Sources
[1]: FDA Genotropin Label
[2]: Pediatric Endocrine Society Guidelines
[3]: Bone Age Assessment in GH Therapy
[4]: Growth Response Studies
[5]: EMA Genotropin Summary